Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
723.41
+10.64 (1.49%)
Yopilishda: May 12, 2026, 4:00 PM EDT
722.99
-0.42 (-0.06%)
Bozor oldidan: May 13, 2026, 4:34 AM EDT
Regeneron Pharmaceuticals, Inc. dunyo bo'ylab turli kasalliklarni davolash uchun dori-darmonlarni kashf qiladi, ixtiro qiladi, ishlab chiqadi, ishlab chiqaradi va tijoratlashtiradi. Kompaniya ko'z, allergik va yallig'lanish, yurak-qon tomir, metabolik, nevrologik, yuqumli va kam uchraydigan kasalliklarni; shuningdek, saraton, gematologik holatlarni davolash uchun mahsulot nomzodlarini ishlab chiqadi. Shuningdek, u namga bog'liq yoshga bog'liq makula degeneratsiyasi va diabetik makula shishini davolash uchun EYLEA in'ektsiyalari; miyopik xorioidal neovaskulyarizatsiya; diabetik retinopatiya; neovaskulyar glaukoma; prematuraga chalinganlik retinopatiyasi; atopik dermatit va astmani davolash uchun Dupixent in'ektsiyasi; metastatik yoki mahalliy rivojlangan teri skuamoz hujayrali karsinomasi uchun Libtayo in'ektsiyasi; geterozigot oilaviy giperxolesterinemiya (HoFH)ni davolash uchun Praluent in'ektsiyasi; va revmatoid artrit uchun Kevzara eritmasini taklif etadi. U EYLEA 8 mg va EYLEAni ishlab chiqish va tijoratlashtirish bo'yicha Bayer bilan litsenziya va hamkorlik shartnomasiga; ko'z va markaziy asab sistemasida ifodalangan terapevtik kasallik maqsadlarini ko'zda tutuvchi kasalliklar uchun RNAi terapevtik vositalarini kashf qilish, ishlab chiqish va tijoratlashtirish bo'yicha Alnylam Pharmaceuticals, Inc. bilan; nevrologik va mushak kasalliklariga qaratilgan terapiyalar uchun in vivo terapevtik rivojlanish uchun CRISPR/Cas9 gen tahriri texnologiyasini ilgari surish bo'yicha Intellia Therapeutics, Inc. bilan; HS-20094, ikki tomonlama GLP-1/GIP retseptorlari uchun ishlab chiqish va tijoratlashtirish huquqlarini sotib olish bo'yicha Hansoh Pharmaceuticals Group Company Limited bilan; va Alpha-1 antitripsin etishmovchiligi uchun TSRA-196, tekshiruv ostidagi gen tahriri terapiyasini ishlab chiqadi va tijoratlashtiradi Tessera Therapeutics, Inc. bilan shartnomalarga ega. Qo'shimcha ravishda, kompaniya radiofarmatsevtik terapiyalarni ishlab chiqish va tijoratlashtirish bo'yicha Telix Pharmaceuticals Limited bilan strategik hamkorlikni yo'lga qo'ygan. Kompaniya 1988 yilda tashkil etilgan va Nyu-Yorkning Tarrytown shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Andrew J. Murphy Ph.D. | Executive VP of Research & Co-Chief Scientific Officer |
| Dr. George D. Yancopoulos M.D., Ph.D. | Co-Founder, President, Chief Scientific Officer & Co-Chairman |
| Dr. Leonard S. Schleifer M.D., Ph.D. | Co-Founder, President, CEO & Co-Chairman |
| Mr. Christopher R. Fenimore CPA | Executive VP of Finance & CFO |
| Mr. Daniel P. Van Plew | Executive VP and GM of Industrial Operations & Product Supply |
| Mr. Joseph J. LaRosa J.D. | Executive VP, General Counsel & Secretary |
| Mr. Rajesh Ahuja | Senior Vice President of Quality Assurance & Operations |
| Mr. Ryan Crowe | Senior Vice President of Investor Relations & Strategic Analysis |
| Mr. Ryan Steinberger | Executive VP, Chief Digital & Technology Officer |
| Ms. Melissa Lozner | Senior VP & Chief Compliance Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-29 | 8-K | regn-20260429.htm |
| 2026-04-29 | 10-Q | regn-20260331.htm |
| 2026-04-24 | DEFA14A | a2026regeneronpharmaceutic.htm |
| 2026-04-08 | 8-K | tm2611354d1_8k.htm |
| 2026-02-04 | 10-K | regn-20251231.htm |
| 2026-01-30 | 8-K | regn-20260130.htm |
| 2026-01-12 | 8-K | tm262861d1_8k.htm |
| 2025-10-28 | 10-Q | regn-20250930.htm |
| 2025-10-06 | 8-K | tm2528010d1_8k.htm |
| 2025-08-01 | 8-K | regn-20250801.htm |